COMMUNIQUÉS West-GlobeNewswire

Ocugen to Present at the 2025 Cell & Gene Meeting on the Med
08/04/2025
MALVERN, Pa., April 08, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri [...]
PDS Biotech Announces PDS01ADC Clinical Data to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025
08/04/2025
NCI presentation to highlight IL-12 fused antibody drug conjugate during poster presentation PRINCETON, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “ [...]
Lantern Names CTO, deepens investment in Specialty Care Platform
08/04/2025
Former Accolade Executive brings scale and innovation to market leader DALLAS, April 08, 2025 (GLOBE NEWSWIRE) -- Lantern , the Specialty Care Platform connecting 6 million members with the best surgery, cancer and [...]
Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases
08/04/2025
First pediatric patient shows encouraging early safety profile and meaningful improvement in visual function at one month A second pediatric patient was recently dosed, and the pediatric cohort is expected to complete [...]
Praxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic Encephalopathies
08/04/2025
BOSTON, April 08, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous [...]
Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Surveillance in Mantle Cell Lymphoma
08/04/2025
clonoSEQ is now covered to monitor for recurrence in MCL patients who are in treatment-free remission SEATTLE, April 08, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage [...]
Vivex Biologics, Inc. Provides Enrollment Update for its ASCEND Study Examining Whether Supplementing Discs with VIA Disc NP™ Reduces Pain and/or Improves Function in Patients with Symptomatic Disc Degeneration
08/04/2025
Data readout expected in Q1 2026 MIAMI, April 08, 2025 (GLOBE NEWSWIRE) -- Vivex Biologics, Inc., a leader in developing and delivering innovative allografts, today announced the company has enrolled 50% of the patients [...]
NeuroPace Announces Data From a Long-Term Post-Approval Study of the RNS System in Focal Epilepsy at the 2025 AAN Annual Meeting
08/04/2025
Three-year data from the largest FDA-reviewed prospective neuromodulation study of safety and effectiveness in drug-resistant focal epilepsy 1 Long-term seizure reduction with a median reduction of 82% at 3 years. [...]
Bionano Announces French Publication of an Effective Method for Analysis of Multiple Myeloma by OGM
08/04/2025
SAN DIEGO, April 08, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a study published in The Journal of Molecular Diagnostics that describes a method for analysis of multiple myeloma (MM [...]
Clene Presents Evidence of Remyelination and Neuronal Repair With CNM-Au8® Treatment At the American Academy of Neurology Late-Breaking Science Session
08/04/2025
Analyses of MRI and VEP data confirm anatomical and physiological improvements, indicating remyelination and neuronal repair in the brains of MS patients treated with CNM-Au8 during the long-term extension of VISIONARY- [...]
SCYNEXIS to Present Preclinical Data on Second Generation IV/Oral Fungerp SCY-247 at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
08/04/2025
JERSEY CITY, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, [...]
Jupiter Neurosciences Highlights Upcoming Milestones in Shareholder Letter
08/04/2025
Strategic expansion into longevity market creates near-term commercial opportunity alongside continued clinical advancement of JOTROL ™ JOTROL ™ development programs remain tariff-exempt; consumer longevity line on [...]
Science 37 Completes Second FDA Inspection as Enrollment Leader in Phase 3 Asthma Trial
08/04/2025
MORRISVILLE, N.C., April 08, 2025 (GLOBE NEWSWIRE) -- Science 37 , a leader in enhancing patient access to clinical trials, today announced the successful completion of its second FDA inspection, reaffirming the quality [...]
ZyVersa Therapeutics CEO Issues Shareholder Letter on PARASOL Recommendations Expected to Reduce Drug Development Barrier for Rare Kidney Disease, Focal Segmental Glomerulosclerosis (FSGS)
08/04/2025
WESTON, Fla., April 08, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with [...]
SIGA Declares Special Cash Dividend of $0.60 Per Share
08/04/2025
NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that its board of directors declared a special cash dividend of $0. [...]
Repligen Appoints Jacob Johnson As Vice President Investor Relations
08/04/2025
WALTHAM, Mass., April 08, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment of Jacob Johnson as Vice President, Investor Relations. In this role, Mr. Johnson will lead the [...]
Cormedix Inc. Announces Preliminary First Quarter 2025 Results and Raises H1 2025 Net Sales Guidance
08/04/2025
‒ Q1 2025 Unaudited Net Revenue of $39.0 million ‒ ‒ Expected Q1 Adjusted EBITDA above $22.5 million ‒ ‒ Q1 2025 Cash and Cash Equivalents of Approximately $77.5 million ‒ BERKELEY HEIGHTS, N.J., April 08, 2025 (GLOBE [...]
Kura Oncology and Kyowa Kirin Announce Submission of New Drug Application for Ziftomenib to FDA
08/04/2025
– Submission seeks approval for the treatment of adult patients with relapsed or refractory AML with a NPM1 mutation – SAN DIEGO and TOKYO, April 08, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, “Kura”), [...]
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting
08/04/2025
NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis [...]

Pages